Glenmark gets USFDA nod for oral contraceptive pills

Glenmark Pharmaceuticals

Drug firm Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic contraceptive norgestimate and ethinyl estradiol tablets.

Glenmark Generics Inc, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the US Food and Drug Administration (USFDA) for Norgestimate and Ethinyl Estradiol tablets in the strengths of 0.25 mg/0.035 mg, Glenmark Pharmaceuticals said in a statement.

The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets.

Citing IMS Health data for the 12-month period ending December 2011, the company said norgestimate and ethinyl estradiol tablets of strength 0.25 mg/0.035 mg garnered total market sales of approximately USD 88 million.

The company currently has 79 generic products authorised for distribution in the US market and 39 ANDA's pending approval with the USFDA, Glenmark said.

Today's approval is Glenmark's tenth female hormonal product authorised for distribution by the USFDA, it added.

Shares of Glenmark Pharmaceuticals were today trading at Rs 307.40 in the morning trade on BSE, down 0.47 per cent from its previous close.

Please read our terms of use before posting comments
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
comments powered by Disqus